SIGN UP

Hugo Fry, Topas Therapeutics CEO

May 5, 2025 03:01 AM EDTUpdated 06:18 AM

Exclusive: Topas claims success in early test of 'immune tolerance' therapy for celiac disease

Ryan Cross

Senior Science Correspondent

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Recursion cuts nearly half of its pipeline, including its most advanced program

Exclusive: Deerfield secures $600M+ for third healthcare venture fund to seed new companies

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges